Catalog # |
Size |
Price |
|
|---|---|---|---|
| RK-054-02 | 125 tubes | $880 |
| View/Download (PDF) - for reference only | |||||||||||||||||||||||
|
| Suggested Procedure | ||||||||||||||||||||||
|
| Recommended | ||||||||||||||||||||||
 Data may differ slightly based on lot. | 70.9 pg/ml | ||||||||||||||||||||||
|
| 10 - 1280 pg/ml | ||||||||||||||||||||||
| |||||||||||||||||||||||
|
| Each kit contains 1.5 µCi of Iodine 125. | ||||||||||||||||||||||
|
| This package conforms to the 49 CFR173.421 for expected radioactive material limited quantity, N.O.S. UN2910. | ||||||||||||||||||||||
  |
 |
CONTEXT: There is no rapid and cost effective tool that can be implemented as a front-line screening tool for Alzheimer's disease (AD) at the population level.OBJECTIVE: To generate and cross-validate a blood-based screener for AD that yields acceptable accuracy across both serum and plasma.DESIGN, SETTING, PARTICIPANTS: Analysis of serum biomarker proteins were conducted on 197 Alzheimer's disease (AD) participants and 199 control participants from the Texas Alzheimer's Research Consortium (TARC) with further analysis conducted on plasma proteins from 112 AD and 52 control participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI). The full algorithm was derived from a biomarker risk score, clinical lab (glucose, triglycerides, total cholesterol, homocysteine), and demographic (age, gender, education, APOE*E4 status) data.MAJOR OUTCOME MEASURES: Alzheimer's disease.RESULTS: 11 proteins met our criteria and were utilized for the biomarker risk score. The random forest (RF) biomarker risk score from the TARC serum samples (training set) yielded adequate accuracy in the ADNI plasma sample (training set) (AUC = 0.70, sensitivity (SN) = 0.54 and specificity (SP) = 0.78), which was below that obtained from ADNI cerebral spinal fluid (CSF) analyses (t-tau/Aβ ratio AUC = 0.92). However, the full algorithm yielded excellent accuracy (AUC = 0.88, SN = 0.75, and SP = 0.91). The likelihood ratio of having AD based on a positive test finding (LR+) = 7.03 (SE = 1.17; 95% CI = 4.49-14.47), the likelihood ratio of not having AD based on the algorithm (LR-) = 3.55 (SE = 1.15; 2.22-5.71), and the odds ratio of AD were calculated in the ADNI cohort (OR) = 28.70 (1.55; 95% CI = 11.86-69.47).CONCLUSIONS: It is possible to create a blood-based screening algorithm that works across both serum and plasma that provides a comparable screening accuracy to that obtained from CSF analyses.
O'bryant SE, Xiao G, Barber R, et al. PLoS ONE. 2011;6(12):e28092.
GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome.
Hellström et al. Neurogastroenterol Motil. 2008 Jun;20(6):649-59.
Pancreatic polypeptide in obese children before and after weight loss.
Reinehr et al. Int J Obes (Lond). 2006 Oct;30(10):1476-81.
Abnormal ghrelin and pancreatic polypeptide responses in gastroparesis.
Gaddipati et al. Dig Dis Sci. 2006 Aug;51(8):1339-46.
Differential effects of sham feeding and meal ingestion on ghrelin and pancreatic polypeptide levels: evidence for vagal efferent stimulation mediating ghrelin release.
Simonian et al. Neurogastroenterol Motil. 2005 Jun;17(3):348-54.
A meal stimulation test in the diagnosis of pancreatic endocrine tumors in multiple endocrine neoplasia type 1.
Migliori et al. Endocrine. 2002 Apr;17(3):229-32.
Secretion of pancreatic icosapeptide from porcine pancreas.
Amaratunga et al. Endocrinology. 2001 Oct;142(10):4314-9.
Social Network Confirmation